CANDIDATE:

Destination Therapy

for patients who are not candidates for a heart transplant

Clinical scenario: After myocardial infarction (MI) on December 27, 2022, his local hospital implanted an Impella hoping to stabilize him. Temporary pump was unsuccessful and he was transferred to Columbia Hosptial for LVAD evaluation.

LVAD Implant

Clinical Presentation:

- Shortness of breath, trouble maintaining blood pressure, MI on December 22, 2022
- EF: 14-16%

Device: HeartMate 3 LVAD

LVAD Implant Date: December 22, 2022

Age at Implant: 76

Procedure: Full-Sternotomy

Post-implant: Aortic dissection during LVAD implant caused a lengthy recovery. Discharged more than two months after implant.

Wiji R

- **79 yr old man**
- **Bio/Activity**: A retired general surgeon living in New York, Dr. Wiji was diagnosed with congestive heart failure and ischemic heart disease, with an ejection fraction of only 14-16%. Despite undergoing angioplasty in 1999 and an unsuccessful Impella pump procedure in 2022, his condition progressed to NYHF Class IV. After a heart attack in December 2022, he was transferred to Columbia Hospital, where he received his LVAD at age 76.

Medical History

Diagnosis: CHF; Ischemic Heart Disease

Medications: Carvedilol, Metformin and Statin

Other Procedures: Angioplasty in 1999, Impella in 2022

HF Classification: NYHF Class IV

Living with LVAD

"The LVAD has given me another lease on life. Nearly three more years and counting. I could not have asked for more."

"A lot of doctors don't know about the LVAD. This information needs to be disseminated better. Getting a referral to heart failure specialists is important. As a general surgeon, I was surprised that even I didn't know about it."

Abbott
6101 Stoneridge Dr., Pleasanton, CA 94588 USA,
Tel: 1 925 847 8600

cardiovascular.abbott/lvad-patient-case-study-profiles

These testimonials relate an account of an individual's response to the treatment. The patient's account is genuine, typical and documented. However, it does not provide any indication, guide, warranty or guarantee as to the response other persons may have to the treatment. Responses to the treatment discussed can and do vary and are specific to the individual patient.

Rx Only
Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

HeartMate 3™ LVAS Indications: The HeartMate 3™ Left Ventricular Assist System is indicated for providing short- and long-term mechanical circulatory support (e.g., as bridge to transplant or myocardial recovery, or destination therapy) in adult and pediatric patients with advanced refractory left ventricular heart failure and with an appropriate body surface area.

HeartMate 3™ LVAS Contraindications: The HeartMate 3 Left Ventricular Assist System is contraindicated for patients who cannot tolerate, or who are allergic to, anticoagulation therapy.

HeartMate 3™ LVAS Adverse Events: Adverse events that may be associated with the use of the HeartMate 3 Left Ventricular Assist System are: death, bleeding, cardiac arrhythmia, localized infection, right heart failure, respiratory failure, device malfunctions, driveline infection, renal dysfunction, sepsis, stroke, other neurological event (not stroke-related), hepatic dysfunction, psychiatric episode, venous thromboembolism, hypertension, arterial non-central nervous system (CNS) thromboembolism, pericardial fluid collection, pump pocket or pseudo pocket infection, myocardial infarction, wound dehiscence, hemolysis (not associated with suspected device thrombosis) or pump thrombosis.

™ Indicates a trademark of the Abbott group of companies.
‡ Indicates a third party trademark, which is property of its respective owner.
© 2026 Abbott. All Rights Reserved.
MAT-2515405 v2.0 | Item approved for U.S. use only.